In an internal open letter, Zhang Yiming said that since its establishment, ByteDance has been fortunate to seize the opportunity of the development of the times, innovate and practice in the field of mobile terminals and videos based on machine learning technology, and has made some achievements. Although the company's business is developing well, I hope that the company will continue to make greater breakthroughs in innovation and become more creative and meaningful.
Therefore, Zhang Yiming decided to put down the daily management of the company and focus on long-term important issues such as long-term strategy, corporate culture and social responsibility. He plans to "focus on learning knowledge, think systematically, study new things, try and experience, and create more possibilities for the company for ten years".
In Zhang Yiming's view, the external environment faced by technology companies is changing: the impact of virtual reality, life science and scientific computing on human life has gradually emerged, and the impact of technology on society is also growing. These factors determine that ByteDance "needs to break through the inertia of business to explore and continuously learn how enterprises can better assume social responsibilities".
Charity in Zhang Yiming:
2019 10/0, Zhang Yiming donated10 billion yuan to his alma mater, Nankai University, to set up the Nankai University Innovation Fund, and supported the innovation and entrepreneurship projects of Nankai teachers, students and graduates through public welfare.
In July, 2020, he was selected into the Forbes 2020 China Charity List, ranking 32nd, with a total cash donation of 1 1 1,000,000 yuan.
In February, 2020, Zhang Yiming donated 6,543.8+billion yuan as a medical aid fund in ByteDance, which was used to donate frontline medical staff to fight the epidemic.
12 On May 20th, Zhang Yiming donated100000 USD to the "COVID-19 Therapeutic Accelerator" project initiated by the Gates Foundation for the research and development of therapeutic drugs for COVID-19.